Related Experiment Video
Updated: Jun 29, 2025
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
Novel CDK19-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake
Dong Dai1,2, Jiang Yu3, Wenfeng Gou3
1Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for China, Tianjin 300060, China.
Abstract:
Cyclin-dependent kinase 19 (CDK19) is overexpressed in prostate cancer, making it an attractive target for both imaging and therapy. Since little is known about the optimized approach for radioligands of nuclear proteins, linker optimization strategies were used to improve pharmacokinetics and tumor absorption, including the adjustment of the length, flexibility/rigidity, and hydrophilicity/lipophilicity of linkers. Molecular docking was conducted for virtual screening and followed by IC50 determination. Both BALB/c mice and P-16 xenografts were used for tissue distribution and PET/CT imaging. The ligand Ga-10c demonstrated high absorption in tumor 5 min after injection and sustains long-term imaging within 3 h. Furthermore, Ga-10c exhibited slow clearance within the tumor and was predominantly metabolized in both the liver and kidneys, showing the potential to alleviate metabolic pressure and enhance tissue safety. Therefore, the linker optimization strategy is well suited for CDK19 and provides a reference for the radioactive ligands of other nuclear targets.
Insights
Linker optimization improved radioligands targeting cyclin-dependent kinase 19 (CDK19) in prostate cancer. The developed radioligand, ⁶⁸Ga-10c, shows promising tumor uptake and retention for imaging.
Area of Science:
- Nuclear medicine
- Radiopharmaceutical chemistry
- Oncology
Background:
- Cyclin-dependent kinase 19 (CDK19) is overexpressed in prostate cancer.
- CDK19 is a potential target for cancer imaging and therapy.
- Optimized radioligands are needed for nuclear protein targets.
Purpose of the Study:
- To optimize linker strategies for radioligands targeting CDK19.
- To develop and evaluate a novel CDK19-targeting radioligand for prostate cancer imaging.
Main Methods:
- Linker optimization (length, flexibility, lipophilicity).
- Molecular docking for virtual screening.
- In vitro IC₅₀ determination.
- In vivo tissue distribution and PET/CT imaging in mice.
Main Results:
- The optimized ligand ⁶⁸Ga-10c showed high tumor uptake within 5 minutes.
- Sustained imaging signal within 3 hours post-injection.
- Slow clearance in tumors and metabolism in liver/kidneys, suggesting improved safety.
Conclusions:
- Linker optimization is effective for developing CDK19 radioligands.
- ⁶⁸Ga-10c demonstrates potential for prostate cancer imaging.
- This strategy serves as a reference for targeting other nuclear proteins.
More Related Videos
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
